COVID-19: immunopathology and its implications for therapy
Identifieur interne : 000653 ( Main/Exploration ); précédent : 000652; suivant : 000654COVID-19: immunopathology and its implications for therapy
Auteurs : Xuetao Cao [République populaire de Chine]Source :
- Nature Reviews. Immunology [ 1474-1733 ] ; 2020.
Abstract
Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Significant antibody production is observed; however, whether this is protective or pathogenic remains to be determined. Defining the immunopathological changes in patients with COVID-19 provides potential targets for drug discovery and is important for clinical management.
Url:
DOI: 10.1038/s41577-020-0308-3
PubMed: 32273594
PubMed Central: 7143200
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000014
- to stream Pmc, to step Curation: 000014
- to stream Pmc, to step Checkpoint: 000558
- to stream Ncbi, to step Merge: 000D27
- to stream Ncbi, to step Curation: 000D27
- to stream Ncbi, to step Checkpoint: 000D27
- to stream Main, to step Merge: 000654
- to stream Main, to step Curation: 000653
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: immunopathology and its implications for therapy</title>
<author><name sortKey="Cao, Xuetao" sort="Cao, Xuetao" uniqKey="Cao X" first="Xuetao" last="Cao">Xuetao Cao</name>
<affiliation wicri:level="1"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9878 7032</institution-id>
<institution-id institution-id-type="GRID">grid.216938.7</institution-id>
<institution>Laboratory of Immunity and Inflammation,</institution>
<institution>College of Life Science, Nankai University,</institution>
</institution-wrap>
Tianjin, China</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Tianjin</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0662 3178</institution-id>
<institution-id institution-id-type="GRID">grid.12527.33</institution-id>
<institution>Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences,</institution>
<institution>Chinese Academy of Medical Sciences,</institution>
</institution-wrap>
Beijing, China</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">32273594</idno>
<idno type="pmc">7143200</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7143200</idno>
<idno type="RBID">PMC:7143200</idno>
<idno type="doi">10.1038/s41577-020-0308-3</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">000014</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000014</idno>
<idno type="wicri:Area/Pmc/Curation">000014</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000014</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000558</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000558</idno>
<idno type="wicri:Area/Ncbi/Merge">000D27</idno>
<idno type="wicri:Area/Ncbi/Curation">000D27</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D27</idno>
<idno type="wicri:doubleKey">1474-1733:2020:Cao X:covid:immunopathology:and</idno>
<idno type="wicri:Area/Main/Merge">000654</idno>
<idno type="wicri:Area/Main/Curation">000653</idno>
<idno type="wicri:Area/Main/Exploration">000653</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">COVID-19: immunopathology and its implications for therapy</title>
<author><name sortKey="Cao, Xuetao" sort="Cao, Xuetao" uniqKey="Cao X" first="Xuetao" last="Cao">Xuetao Cao</name>
<affiliation wicri:level="1"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9878 7032</institution-id>
<institution-id institution-id-type="GRID">grid.216938.7</institution-id>
<institution>Laboratory of Immunity and Inflammation,</institution>
<institution>College of Life Science, Nankai University,</institution>
</institution-wrap>
Tianjin, China</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Tianjin</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0662 3178</institution-id>
<institution-id institution-id-type="GRID">grid.12527.33</institution-id>
<institution>Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences,</institution>
<institution>Chinese Academy of Medical Sciences,</institution>
</institution-wrap>
Beijing, China</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature Reviews. Immunology</title>
<idno type="ISSN">1474-1733</idno>
<idno type="eISSN">1474-1741</idno>
<imprint><date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="Par1">Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Significant antibody production is observed; however, whether this is protective or pathogenic remains to be determined. Defining the immunopathological changes in patients with COVID-19 provides potential targets for drug discovery and is important for clinical management.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Huang, C" uniqKey="Huang C">C Huang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Xu, Z" uniqKey="Xu Z">Z Xu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Qin, C" uniqKey="Qin C">C Qin</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Zheng, M" uniqKey="Zheng M">M Zheng</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Shen, C" uniqKey="Shen C">C Shen</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Zhao, J" uniqKey="Zhao J">J Zhao</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Runfeng, L" uniqKey="Runfeng L">L Runfeng</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Cao, Xuetao" sort="Cao, Xuetao" uniqKey="Cao X" first="Xuetao" last="Cao">Xuetao Cao</name>
</noRegion>
<name sortKey="Cao, Xuetao" sort="Cao, Xuetao" uniqKey="Cao X" first="Xuetao" last="Cao">Xuetao Cao</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000653 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000653 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= StressCovidV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:7143200 |texte= COVID-19: immunopathology and its implications for therapy }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32273594" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a StressCovidV1
This area was generated with Dilib version V0.6.33. |